Therapeutic human anti-il-1r1 monoclonal antibody
AssigneesMedarex, Inc., Amgen Inc.
InventorsBrian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
Life of this patent
Estimating the term…
Abstract
Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Claims15
1-61. (canceled)
An isolated antibody or antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising:
- (a) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO:
- 84, or the antigen binding fragment thereof, and the light chain comprises a light chain variable region comprising SEQ ID NO:
- 83, or the antigen binding fragment thereof, wherein the antigen binding fragment of the heavy chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO:
- 84 comprising at least SEQ ID NO:
- 61, SEQ ID NO:64, and SEQ ID NO:
- 67, and the antigen binding fragment of the light chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO:
- 83 comprising at least SEQ ID NO:
- 70, SEQ ID NO:
- 72, and SEQ ID NO:
- 74;
- or
- (b) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO:
- 82, or the antigen binding fragment thereof, and the light chain comprises a light chain variable region comprising SEQ ID NO:
- 83, or the antigen binding fragment thereof, wherein the antigen binding fragment of the heavy chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO:
- 82 comprising at least SEQ ID NO:
- 62, SEQ ID NO:65, and SEQ ID NO:
- 68, and the antigen binding fragment of the light chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO:
- 83 comprising at least SEQ ID NO:
- 70, SEQ ID NO:
- 72, and SEQ ID NO:
- 74.
An isolated antibody or antigen binding fragment thereof comprising:
- (a) a human heavy chain comprising human heavy chain framework regions, a human heavy chain CDR1 region comprising SEQ ID NO:
- 61, a human heavy chain CDR2 region comprising SEQ ID NO:
- 64, and a human heavy chain CDR3 region comprising SEQ ID NO:
- 67;
- and a human light chain comprising human light chain framework regions, a human light chain CDR1 region comprising SEQ ID NO:
- 70, a human light chain CDR2 region comprising SEQ ID NO:
- 72, and a human light chain CDR3 region comprising SEQ ID NO:
- 74;
- or
- (b) a human heavy chain comprising human heavy chain framework regions, a human heavy chain CDR1 region comprising SEQ ID NO:
- 62, a human heavy chain CDR2 region comprising SEQ ID NO:
- 65, and a human heavy chain CDR3 region comprising SEQ ID NO:
- 68;
- and a human light chain comprising human light chain framework regions, a human light chain CDR1 region comprising SEQ ID NO:
- 70, a human light chain CDR2 region comprising SEQ ID NO:
- 72, and a human light chain CDR3 region comprising SEQ ID NO:
- 74.
An isolated antibody or an antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising:
- (a) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO:
- 84;
- or
- (b) a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO:
- 82;
- or
- (c) a heavy chain and a light chain, wherein the light chain comprises a light chain variable region comprising SEQ ID NO:
- 83.
Dependencies are inferred from the claim text.